Live Analyst Rating Changes 1505 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Kalpit Patel
WLF
Kalpit Patel
Wolfe Research
Wall Street Analyst
★☆☆☆☆
#2352
on 13Foresight · ranked by our own returns
50%
Success Rate
-2.3%
Average Return
17 of 34 calls profitable · -16.9% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 50% of Kalpit Patel's ratings turned a profit when each position was held for 1 year — averaging -2.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

12 Buy 7 Hold 1 Sell
Kalpit's Stock Coverage 33 ratings · 2026-06-18
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
GMAB
Genmab
 Jun 14, 2026 BUY Buy
+38.1% avg upside
26 analysts
$32.00
26.77% Upside
 ·
TNGX
Tango Therapeutics
 Jun 08, 2026 BUY Strong Buy
+11.8% avg upside
14 analysts
$35.00
24.55% Upside
 +6.4%
ONC
BeOne Medicines
 Jun 03, 2026 BUY Strong Buy
+31.0% avg upside
28 analysts
$340.00
25.84% Upside
 -5.9%
CGON
CG Oncology, Inc.
 May 26, 2026 HOLD Strong Buy
+42.0% avg upside
17 analysts
 — -4.0%
TYRA
Tyra Bioscience
 May 19, 2026 HOLD Strong Buy
+55.7% avg upside
17 analysts
 — -3.8%
MIRM
Mirum Pharmaceuticals
 May 19, 2026 BUY Strong Buy
+10.1% avg upside
21 analysts
$145.00
36.41% Upside
 +12.0%
CTMX
CytomX Therapeutics
 May 19, 2026 BUY Strong Buy
+268.7% avg upside
21 analysts
$6.00
104.74% Upside
 -17.3%
RVMD
Revolution Medicines
 May 06, 2026 BUY Strong Buy
-10.2% avg upside
32 analysts
$165.00
2.85% Upside
 +4.4%
KRYS
Krystal Biotech
 Mar 26, 2026 HOLD Strong Buy
-27.6% avg upside
19 analysts
 — +35.9%
OLMA
Olema Pharmaceuticals
 Mar 26, 2026 HOLD Strong Buy
+309.3% avg upside
16 analysts
 — -34.9%
CORT
Corcept Therapeutics
 Mar 26, 2026 HOLD Buy
-46.3% avg upside
15 analysts
 — +112.2%
VSTM
Verastem
 Oct 10, 2025 BUY Strong Buy
+254.8% avg upside
23 analysts
$16.00
281.00% Upside
 -53.3%
AVBP
ArriVent BioPharma, Inc.
 Jul 21, 2025 BUY Strong Buy
+38.0% avg upside
15 analysts
$37.00
17.05% Upside
 +45.5%
MNOV
Medicinova
 Jun 16, 2025 BUY Strong Buy
+456.7% avg upside
5 analysts
$5.00
275.90% Upside
 +3.0%
KYMR
Kymera Therapeutics
 Jun 03, 2025 BUY Strong Buy
+9.5% avg upside
36 analysts
$60.00
33.16% Downside
 +68.0%
VRDN
Viridian Therapeutics
 May 21, 2025 HOLD Strong Buy
+102.9% avg upside
32 analysts
$19.00
14.71% Upside
 +17.9%
CRBP
Corbus Pharmaceuticals
 May 07, 2025 BUY Strong Buy
+346.7% avg upside
20 analysts
$28.00
244.01% Upside
 +77.3%
BCYC
Bicycle Therapeutics
 May 02, 2025 HOLD Strong Buy
+502.2% avg upside
20 analysts
$14.00
250.98% Upside
 -48.4%
DERM
Journey Medical Corp
 Mar 27, 2025 BUY Strong Buy
+108.6% avg upside
11 analysts
$9.00
52.47% Upside
 -22.8%
RIGL
Rigel
 Mar 05, 2025 HOLD Strong Buy
-28.0% avg upside
17 analysts
$24.00
27.10% Downside
 +45.5%
SNDX
Syndax Pharmaceuticals
 Mar 03, 2025 BUY Strong Buy
+87.3% avg upside
27 analysts
$29.00
50.63% Upside
 +38.2%
GERN
Geron
 Feb 26, 2025 HOLD Strong Buy
+241.8% avg upside
19 analysts
$2.00
56.27% Upside
 +2.5%
FHTX
Foghorn Therapeutics
 Jan 29, 2025 BUY Strong Buy
+191.1% avg upside
17 analysts
$10.00
141.51% Upside
 +45.0%
XFOR
X4 Pharmaceuticals
 Nov 18, 2024 HOLD Strong Buy
+513.8% avg upside
15 analysts
$15.00
260.58% Upside
 -67.6%
OVID
Ovid Therapeutics
 Sep 27, 2024 BUY Strong Buy
+98.5% avg upside
17 analysts
$3.00
28.97% Upside
 +46.6%
ALLO
Allogene Therapeutics
 May 14, 2024 BUY Strong Buy
+673.3% avg upside
28 analysts
$7.00
249.19% Upside
 -67.9%
PDSB
PDS Biotechnology
 Aug 14, 2023 BUY Strong Buy
+1583.2% avg upside
11 analysts
$14.00
1434.32% Upside
 -43.3%
INKT
MiNK Therapeutics
 Mar 21, 2023 BUY Strong Buy
+79.7% avg upside
6 analysts
$7.00
41.71% Downside
 -56.4%
DNTH
Dianthus Therapeutics
 Dec 30, 2022 HOLD Strong Buy
+9.8% avg upside
29 analysts
 — +62.5%
INAB
IN8bio
 Dec 30, 2022 HOLD Strong Buy
+3983.6% avg upside
5 analysts
 — -40.3%
INFIQ
Infinity Pharmaceuticals
 Dec 30, 2022 HOLD Buy
+647142757.1% avg upside
8 analysts
 — -99.6%
ENTX
Entera Bio
 Aug 19, 2022 HOLD Strong Buy
+351.5% avg upside
3 analysts
 — -62.3%
FBRX
Forte Biosciences
 Nov 26, 2021 HOLD Strong Buy
+129.5% avg upside
14 analysts
 — -63.1%
🔒 28 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Kalpit Patel — Frequently Asked Questions
How accurate are Kalpit Patel's stock ratings?
Based on the calls 13Foresight could measure, about 50% of Kalpit's ratings were profitable over a one-year hold, with an average return of -2.4% per rating, or -17.0% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Kalpit ranked on 13Foresight?
Kalpit Patel is currently ranked #2352 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Kalpit cover?
Kalpit most recently has ratings on GMAB, TNGX, ONC, CGON, TYRA, MIRM, CTMX, RVMD, KRYS, OLMA, CORT, VSTM and 21 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.